Last updated: June 23, 2026
Exela Pharma Sciences, LLC is asserting patent infringement against Hikma Pharmaceuticals USA Inc. in the ANDA patent-litigation action filed in the District of Delaware under caption Exela Pharma Sciences, LLC v. Hikma Pharmaceuticals USA Inc., 1:23-cv-00137. The case’s litigation history, asserted patents, and potential settlement or merits posture are not determinable from the information provided, so an accurate, actionable summary cannot be produced.
What is Exela Pharma Sciences, LLC v. Hikma Pharmaceuticals USA Inc. (1:23-cv-00137) and what claims are at issue?
No complete case record details are available in the prompt. A litigation summary that identifies the asserted patent(s), claims, drug/ANDA at issue, relief sought, procedural posture, and key court rulings cannot be produced without relying on non-provided facts.
What is the case jurisdiction and docket structure?
The matter is identified only by docket number and parties. Without access to filings or the docket text, the timing and stages (complaint, answers, patent contentions, Markman briefing, motion practice, trial scheduling, and any stay events) cannot be stated.
What patents are asserted and how many?
The number and identity of the asserted patents cannot be stated from the prompt. Patent-by-patent infringement and validity analysis requires the specific patent numbers and asserted claims.
Which patents protect the Exela product against Hikma’s ANDA launch?
A protection landscape and “how strong is the patent estate” analysis requires the Orange Book listing(s) for the relevant NDA/ANDA-drug combination and the specific patents Exela asserted in this case. Those inputs are not provided.
How many Orange Book patents are typically asserted in ANDA cases like this?
General patterns exist, but assigning a count and composition (drug substance, formulation, method of use, device, manufacturing) would be speculative.
What does the infringement theory look like (ANDA label vs. product composition)?
Infringement theory depends on the ANDA formulation and Hikma’s proposed label and manufacturing method. Those facts are not included.
When does exclusivity end and what is the generic entry risk for Hikma after this litigation?
Exclusivity and entry-risk analysis depends on the underlying reference-listed drug, NDA maturity, patent expiration dates, and any exclusivity periods. The drug identity is not specified.
What are the relevant expiration dates?
Patent expiration requires patent numbers and their expiration terms (including any PTA, PTE, and regulatory exclusivity interaction). Not provided.
When do Paragraph IV challenges cut off exclusivity and trigger 180-day exclusivity?
That depends on whether Hikma is an ANDA filer with a Paragraph IV certification, whether a first-filer 180-day exclusivity vests, and whether there has been forfeiture due to litigation timing. None of those facts are provided.
How does the court’s procedural posture affect case outcome in 1:23-cv-00137?
Outcome and settlement likelihood hinge on motion rulings and procedural milestones. No filings or orders are provided.
Has the case been stayed pending USPTO reexamination or inter partes review?
Stay events require docket/order data. Not provided.
Have claim constructions (Markman) been issued?
Markman outcomes materially change infringement/validity analysis. Not provided.
What is the settlement and licensing status in Exela v. Hikma?
Settlement status requires docket entries and/or public settlement agreements. The prompt does not contain any settlement information.
Did the parties enter a consent judgment or stipulation of dismissal?
This depends on docket outcomes. Not available from the prompt.
Is there evidence of “carve-out” product or design-around?
Design-around implications depend on the ANDA label/formulation and any negotiated restrictions. Not provided.
What generic launch scenarios are realistic after this litigation?
Launch timing depends on patent expiry, any court-entered injunction status, and whether Hikma’s ANDA is approved or stays are lifted. None of that is present.
What happens if the court grants or denies a preliminary injunction?
Preliminary injunction posture is not provided.
What happens if Hikma’s ANDA is approved “at risk”?
At-risk approval requires FDA approval timelines and any litigation-specific constraints. Not provided.
What Orange Book status applies to the product involved in 1:23-cv-00137?
Orange Book status needs the NDA/Reference Product Name and the Orange Book patent listing set for the relevant formulation(s). Not provided.
Which patents are listed for drug substance vs. formulation vs. method of use?
Not determinable without Orange Book data and asserted patent list.
How strong is the patent estate asserted by Exela in this case?
Patent strength analysis must tie to the asserted patents’ claim scope and the likely validity challenges (anticipation, obviousness, §112, written description, enablement, indefiniteness). That requires the asserted patent text, claims, and the infringement/invalidity theories. None are provided.
What are the likely validity attack points?
Without knowing the patents and claims, no reliable analysis can be offered.
What do non-infringement positions typically rely on?
Those positions depend on the ANDA product’s differences versus the asserted claim elements. Not provided.
Which companies are challenging similar patents and how does this case compare?
Comparison requires identifying the broader patent landscape and other litigations involving the same product and/or patents. The product and patents are not provided.
How does Hikma’s broader ANDA litigation record affect settlement leverage?
That requires cross-case data. Not provided.
How do other generic entrants’ Paragraph IV filings change 180-day exclusivity or injunction risk?
That requires knowing the first-filer status and whether others are parties to related actions. Not provided.
Key Takeaways
- The docket is identified as Exela Pharma Sciences, LLC v. Hikma Pharmaceuticals USA Inc., 1:23-cv-00137.
- A litigation summary and patent-strength analysis cannot be completed from the prompt because no asserted patents, drug/ANDA identity, filings, court orders, or procedural history are provided.
FAQs
- What is the typical remedy sought by ANDA patent plaintiffs in cases like Exela v. Hikma?
- How do patent contentions and claim construction schedules usually drive the timing of infringement rulings in Hatch-Waxman cases?
- What facts determine whether a stay under USPTO proceedings applies in ANDA litigation?
- How is 180-day exclusivity typically analyzed when multiple Paragraph IV filers exist?
- What evidence most often supports design-around defenses in formulation and method-of-use cases?
References
- Exela Pharma Sciences, LLC v. Hikma Pharmaceuticals USA Inc., No. 1:23-cv-00137 (D. Del.).
